10.6084/m9.figshare.5670607.v1
Augusto Afonso Guerra Júnior
Augusto Afonso Guerra
Júnior
Grazielle Dias Silva
Grazielle Dias
Silva
Eli Iola Gurgel Andrade
Eli Iola Gurgel
Andrade
Mariângela Leal Cherchiglia
Mariângela Leal
Cherchiglia
Juliana de Oliveira Costa
Juliana
de Oliveira Costa
Alessandra Maciel Almeida
Alessandra Maciel
Almeida
Francisco de Assis Acurcio
Francisco de Assis
Acurcio
Cyclosporine versus tacrolimus: cost-effectiveness analysis for renal transplantation in Brazil
SciELO journals
2017
Immunosuppressive Agents
therapeutic use
Kidney Transplantation
economics
Graft Survival
Transplantation Tolerance
drug effects
Cost-Benefit Analysis
Unified Health System
Cohort Studies
2017-12-05 15:04:58
Dataset
https://scielo.figshare.com/articles/dataset/Cyclosporine_versus_tacrolimus_cost-effectiveness_analysis_for_renal_transplantation_in_Brazil/5670607
<div><p>OBJECTIVE To analyze the cost-effectiveness of treatment regimens with cyclosporine or tacrolimus, five years after renal transplantation.METHODS This cost-effectiveness analysis was based on historical cohort data obtained between 2000 and 2004 and involved 2,022 patients treated with cyclosporine or tacrolimus, matched 1:1 for gender, age, and type and year of transplantation. Graft survival and the direct costs of medical care obtained from the National Health System (SUS) databases were used as outcome results.RESULTS Most of the patients were women, with a mean age of 36.6 years. The most frequent diagnosis of chronic renal failure was glomerulonephritis/nephritis (27.7%). In five years, the tacrolimus group had an average life expectancy gain of 3.96 years at an annual cost of R$78,360.57 compared with the cyclosporine group with a gain of 4.05 years and an annual cost of R$61,350.44.CONCLUSIONS After matching, the study indicated better survival of patients treated with regimens using tacrolimus. However, regimens containing cyclosporine were more cost-effective.</p></div>